At the news
? BULLISHIMPACT 8/10 8-K filed May 19, 2026 at 10:32 ET
InMed Pharmaceuticals (INM) entered into a definitive agreement to acquire Mentari Therapeutics via reverse merger, with Mentari shareholders receiving a majority stake in the combined entity. A concurrent PIPE of at least $150 million will fund operations and support the merged company's pipeline. The transaction includes a contingent value right for pre-merger INM shareholders and represents a transformative change of control.
- Reverse merger: INM acquires Mentari Therapeutics through merger subsidiaries; Mentari shareholders become majority owners of combined entity.
- Mentari valued at $125 million (base Company Equity Value), subject to upward adjustment from PIPE proceeds.
- Concurrent PIPE of at least $150 million from institutional investors, committed via securities purchase agreement.
- Pre-merger INM shareholders receive one CVR per share, entitling them to future contingent payments.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access